Pancreatic Cancer Research

ResearcherNew York UniversityActive in the last 2 years

Alessio Marchetti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0006-3365-7713; OpenAlex author ID A5015532054. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2025: 5 papers · 2026: 4 papers

Papers 9

  1. Survival benefit of recurrence-focused treatment after surgery for pancreatic ductal adenocarcinoma: A propensity score matched analysis of patients from a Dut… Co-author DOI 10.1016/j.ejca.2026.117776↗
  2. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  3. Postpancreatectomy liver injury: A relevant entity in the modern era of pancreatic cancer surgery with hepatic vessel resection. A monocentric retrospective co… Co-author DOI 10.1016/j.surg.2026.110302↗
  4. Proposal for an Objective and Concrete Definition for Determining Anatomic Resectability in Pancreatic Cancer: The Concept of the "Suitable Target". Co-author DOI 10.1097/xcs.0000000000001738↗
  5. Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer. First author DOI 10.1016/j.surg.2024.109114↗
  6. Neoadjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasm-derived Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006687↗
  7. Carbohydrate Antigen 19-9 Delta Function for Survival Prediction in Borderline Pancreatic Cancer. A PANC-PALS Consortium International Multicenter Derivation a… First author DOI 10.1097/sla.0000000000006735↗
  8. Transitional Type Circulating Tumor Cells Predict Systemic Recurrence and Support Risk Stratification for Chemotherapy After Resection of Pancreatic Ductal Ade… Co-author DOI 10.1097/sla.0000000000006998↗
  9. Two-Stage Mayo Clinic Class IIIb Celiac Axis Resection for Pancreatic Adenocarcinoma: Stepwise Management. Co-author DOI 10.1245/s10434-024-16673-z↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ammar A. Javed · 8 shared papers, 2025–2026 · strength 1.68
  2. Greg D. Sacks · 7 shared papers, 2025–2026 · strength 1.57
  3. Christopher Lee Wolfgang · 6 shared papers, 2025–2026 · strength 1.35
  4. Joseph R. Habib · 6 shared papers, 2025–2026 · strength 1.20
  5. Jonathan Garnier · 5 shared papers, 2025–2026 · strength 1.15
  6. Ingmar Florin Rompen · 5 shared papers, 2025–2026 · strength 1.05
  7. Daniel Brock Hewitt · 5 shared papers, 2025 · strength 1.05
  8. Paul C. M. Andel · 5 shared papers, 2025–2026 · strength 0.99
  9. Camila Hidalgo Salinas · 4 shared papers, 2025–2026 · strength 0.86
  10. Giampaolo Perri · 3 shared papers, 2025–2026 · strength 0.69
  11. Roberto Salvia · 3 shared papers, 2025–2026 · strength 0.61
  12. Lois A. Daamen · 3 shared papers, 2025–2026 · strength 0.57
  13. Izaak Quintus Molenaar · 3 shared papers, 2025–2026 · strength 0.57
  14. Marc G. Besselink · 3 shared papers, 2025–2026 · strength 0.57
  15. Kelly J. Lafaro · 3 shared papers, 2025–2026 · strength 0.55
  16. Michael D. Kluger · 2 shared papers, 2026 · strength 0.52
  17. Giovanni Marchegiani · 2 shared papers, 2025–2026 · strength 0.40
  18. Christopher L. Wolfgang · 2 shared papers, 2025 · strength 0.40
  19. Thijs J. Schouten · 2 shared papers, 2026 · strength 0.39
  20. Jin Peng He · 2 shared papers, 2026 · strength 0.39
  21. Bas Groot Koerkamp · 2 shared papers, 2026 · strength 0.39
  22. Iris W.J.M. van Goor · 2 shared papers, 2026 · strength 0.39
  23. Hjalmar C. van Santvoort · 2 shared papers, 2026 · strength 0.39
  24. Martijn W.J. Stommel · 2 shared papers, 2026 · strength 0.39
  25. Giuseppe Malleo · 2 shared papers, 2025–2026 · strength 0.37

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.